Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Investor Relations

Board of Directors

Mani Mohindru, Ph.D.

Committees: Corporate Governance and Nominating Committee, Audit Committee

Mani Mohindru has been a director since 2021. She is currently the Chief Executive Officer of Novasenta, an early-stage biotechnology company, and a Director on the Board of CytomX, Inc. (Nasdaq: CTMX), a clinical-stage biopharmaceutical company. Dr. Mohindru previously worked in executive roles at several additional biotechnology companies, having served as Chief Executive Officer of CereXis, Inc., Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), and Chief Strategy Officer at Curis, Inc (Nasdaq: CRIS). Prior to her leadership roles in the biotechnology industry, Dr. Mohindru spent several years as an equity research analyst covering the biotechnology sector at UBS, Credit Suisse and ThinkEquity. She also co-founded a privately held biotechnology company and was a healthcare industry consultant. She was also a member of the Board of Directors of SAB Biotherapeutics, a clinical-stage private biopharmaceutical company.

On the non-profit side, Dr. Mohindru is a member of the Executive Advisory Board of the Chemistry of Life Processes Institute of Northwestern University and a member of the Scientific Investment Advisory Committee of the Gates Center of Regenerative Medicine at the University of Colorado. Dr. Mohindru received her Ph.D. in Neurosciences from Northwestern University and her master’s in biotechnology and BS in Human Biology (Hons) from the All-India Institute of Medical Sciences, India.